Changes in human immunodeficiency virus (HIV) type 1 concentration and protease genotype were evaluated in semen specimens from 22 HIV-positive men before and 6 months after the addition of indinavir to dual nucleoside therapy. Seminal HIV was detected by polymerase chain reaction analysis for DNA or RNA for 59% of men before combination treatment and persisted at 6 months for 31% of the men who initially had seminal HIV detected (P Å .026). The maximum levels of cell-free RNA, cell-associated RNA, and proviral DNA in semen before treatment and at 6 months were 400,000 and 10,000 copies/mL, 70,000 and 27,000 copies/mL, and 80,000 and 3,000 copies/mL, respectively. Three of the four men with persistent seminal DNA had plasma viral loads of ú10,000 copies/mL before treatment. One patient who became intolerant to indinavir had seminal HIV RNA detected by PCR analysis after 6 months. Although none of the cultures of semen specimens from the four men with PCR analysis -detectable seminal DNA after 6 months yielded HIV, indinavir resistance mutations were identified in a seminal leukocyte DNA specimen from one patient, and a second patient whose therapy was switched to saquinavir had different protease inhibitor resistance mutations in seminal and blood leukocyte DNA specimens. HIV-1 protease inhibitor resistance mutants may emerge in the semen of patients receiving combination therapy.
The addition of protease inhibitors as a part of combination and express a range of cytotropic and other characteristics in different sites in the body, including the CNS and genital tract antiretroviral therapy has had a profound effect on decreasing morbidity and mortality in HIV-infected patients, paralleling [6 -10] . Patients have been described who have had systemic suppression of HIV replication, but residual HIV infection has significant suppression of HIV replication in plasma [1 -3] . Several protocols have attempted to maximally suppress sysbeen shown by the detection of HIV DNA as provirus in the bone marrow as well as in semen [4, 5, 11] . The significance temic HIV replication in recently infected persons with the goal of HIV eradication, but recent findings suggest that this of this residual HIV DNA is unclear, and it could be either a nonreplicating harbinger of ultimately effective eradication or a suppression may be less feasible than initially thought because of a persistent reservoir of latent memory CD4
/ cells that can sign of relatively quiescent persistent infection. Recent reports presented at the 12th International Conference on AIDS in be reactivated [4, 5] . In addition, HIV is thought to replicate Geneva suggested that multidrug-resistant HIV may be sexually spread (i.e., mutations in HIV reverse transcriptase and protease are not an absolute impediment to HIV replication and transmission) [12] .
resistance mutations before treatment have raised concern that reaction well contained a standardized PCR mixture including 10 mM digoxigenin-labeled dUTP, 2.5 U of DNA polymerase suppression of HIV replication in the genital tract may not be complete [19 -22] . The purpose of the current study was to (Boehringer Mannheim), and 250 copies of internal control DNA (an HIV mimic containing SK38 and SK39 primer bindlongitudinally evaluate the effects of treatment with highly active antiretroviral regimens in the genital tract and to better ing sites with a different internal sequence). One microgram of DNA was used for each test sample and controls, and the understand the potential for the sexual transmission of HIV during such combination therapy.
reaction underwent 35 thermal cycles; 10, 100, 1,000, 10,000, and 100,000 copies of HIV-1 DNA and normal human placenta DNA (Perkin-Elmer) were used as positive and negative conMaterials and Methods trols, respectively, for PCR analysis. Control reagents that contained no DNA were also included. PCR products were quantiStudy participants. The participants in the study were 22 asymptomatic HIV-infected men followed up at the Fenway tated by using an ELISA detection kit (Boehringer Mannheim) with use of three volumes (10 mL, 1 mL, and 0.25 mL) of the Community Health Center (Boston) for primary medical care. All participants acquired HIV infection via male homosexual digoxigenin-labeled PCR product; two PCR products, 10 -mL and 0.25 -mL volumes, were hybridized with 200 mL of a intercourse. The men enrolled in the study between April and August 1996 and provided written informed consent indicating biotin-labeled HIV-1 capture probe, SK19, diluted to a concentration of 7.5 pmol/mL, and the remaining 1 mL of DNA was that before the addition of protease inhibitor therapy, they consented to donate blood and semen specimens and agreed to hybridized with a biotin-labeled internal control probe. Following capture of the hybridized PCR products on a streptavidincontinue to do so after 1 and 6 months of combination antiretroviral therapy. All but two of the men completed the entire coated microtiter plate and subsequent incubation with horseradish peroxidase -conjugated antibody to digoxigenin, a substudy; the conditions of both men who did not provide 6-month semen specimens were clinically stable with undetectable strate solution was added to each well, and the absorbance was read in the ELISA reader at 405 nm. plasma levels of HIV RNA, but these men elected not to continue the study because of the protocol demands. All of the Two standard curves were generated by using the absorbance ratios of HIV-1 to the internal control of the series of positive participants had previously been receiving antiretroviral therapy for at least 6 months with dual nucleoside analog agents, controls. The standard curve generated with 10 mL of PCR product was used for low-copy-number calculations, and one but none had prior treatment with a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor. At the start of the made by diluting 0.25 mL of PCR product was used for highrange calculations. The initial HIV-1 copy number in each study, 15 participants were receiving zidovudine/lamivudine; 4, stavudine/lamivudine; and 3, zidovudine/didanosine. In all sample was determined by plotting its absorbance ratio of HIV to the internal control with use of the standard curve. cases, after baseline blood and semen specimens were obtained, indinavir (800 mg three times a day) was administered in conTo minimize cross-contamination in PCR analysis, steps before, during, and after PCR analysis were performed in separate junction with nucleoside analog therapy.
DNA extraction and PCR analysis of semen cells. Aliquots rooms with individual dedicated pipettes etc. Sterilized filtered pipette tips and negative displacement pipettemen were used of frozen semen cell pellets were thawed at room temperature and digested in 500 mL of differential lysis buffer consisting throughout the procedure, and all preparative work was performed in an isolated laminar flow hood. In addition, each of 10 mM Tris-HCl (pH 8.0), 10 mM EDTA, 50 mM NaCl, 2% SDS, and 300 mg of proteinase K/mL (Boehringer Mannheim, experiment included numerous negative controls (described above). All negative controls remained negative during the Indianapolis) at 50ЊC for 60 minutes on a rotator. The cell lysates were extracted with phenol/chloroform and precipitated study. The intraassay coefficient of variation for logtransformed data ranged from 5.1 to 17.3 for 10 copies of HIV with ethanol [15] . DNA was quantified at 260 nm. Ten million semen cells from HIV-1-seronegative healthy men were in-DNA (8E5 cells), 3.7 to 6.5 for 100 copies of HIV, and 0.2 to 10.9 for 1,000 copies of HIV. The interassay coefficient of cluded as negative controls, and 10 and 100 8E5 human T lymphocyte cells (which contain one HIV type 1 [HIV-1] DNA variation was 38 for 10 copies of HIV, 9 for 100 copies of HIV, and 9 for 1,000 copies of HIV. copy per cell) spiked in 10 7 normal human semen cells were used as positive controls in the preparation step for extraction RNA extraction from seminal plasma and semen cells. Sperm and other cells were isolated from fresh semen speciof semen DNA and underwent the same process afterward as the test specimens to monitor sample-to-sample contamination mens by centrifugation at 400g for 10 minutes; 0.75 mL of Tri reagent (Molecular Research Center, Cincinnati) was added to and carryover of PCR products.
PCR analysis was performed with use of the 9600 GeneAmp up to 5 1 10 6 cells or 250 mL of a 1:1 dilution of seminal plasma. RNA was isolated from the aqueous phase according PCR System (Perkin-Elmer, Norwalk, CT) as previously described in detail [8] . The hot start amplification technique for to the manufacturer's protocol, precipitated and washed twice in isopropanol, dried, dissolved in 10 mL of diethylphosphoryl PCR analysis was used with primers specific for the gag region of the HIV-1 gene, SK38 and SK39 (Perkin-Elmer) [15] . Each cyanide -treated water, and quantitated at 260 nm. with a different method (Puregene DNA isolation kit; Gentra Systems, Minneapolis; this procedure was followed by extracvirus reverse transcriptase, and 2.5 mM downstream primer (SK39). The reaction mixture was incubated at 22ЊC for 10 tion with phenol/chloroform and ethanol precipitation) was successful. Additional cell aliquots were not available from paminutes and then at 42ЊC for 30 minutes followed by heating at 99ЊC for 5 minutes. Forty microliters of the PCR reagent tients for whom semen cell DNA could not be amplified at the other times, except for the blood and semen cells collected at mixture was added to each tube while incubating the tubes at 4ЊC. After initial heating at 99ЊC for 2 minutes, PCR analysis the 18-month time from patient A (which were also prepared with the Puregene DNA isolation kit). for DNA was performed as described above. Negative and external positive controls were normal human sperm spiked PCR products from several independent reactions were pooled and cloned into the plasmid vector pJM2, except for with 0, 250, 500, and 2,500 recombinant Moloney virus particles carrying a synthetic HIV-1 gag fragment with a deletion those amplified from the baseline semen specimen from patient B [23] . Competent DH10B cells (GIBCO BRL, Burlington, (National Institutes of Health AIDS Repository), and these controls underwent the same procedures for RNA extraction Ontario, Canada) were transformed by electroporation. Bacteria were plated on lysed blood medium containing 100 mg of and reverse transcription PCR analysis.
Amplification, cloning, and sequencing of protease genes. ampicillin/mL and incubated at 37ЊC overnight. Individual transformed colonies of Escherichia coli were analyzed for the HIV-1 protease was amplified for cloning and sequencing by means of hot start nested PCR analysis after other virological presence of a recombinant insert by restriction endonuclease digestion (HincII; New England BioLabs, Beverly, MA). assays of 1 mg of previously titered semen cell DNA lysates remaining from quantitative assays were performed. Three
Ten recombinant clones were sequenced from each semen specimen with use of dye-labeled primers gag 1880 (5-CTGrounds of PCR amplification were needed because of the low copy number (three to 90 copies) of input HIV-1 DNA in a AAGCAATGAGCCAAGTAACAAAT) and 3F P12 (5-CTG-CGGGATGTGGTATTCCTAA) for cycle sequencing (Therreaction. In the first round, 50 pmol of the primers 5CAI1988 (including positive-strand nucleotides 1,987 to 2,014 of HxB2) moSequenase; Amersham International, Amersham, United Kingdom) with an automated sequencer (ALF; Pharmacia, Pisand 3CAI4226 (including negative-strand nucleotides 4,254 to 4,225 of HxB2) were used in 100 mL of a reaction mixture cataway, NJ). The PCR product amplified from the baseline semen cell specimen from patient B was adequate for bulk containing 200 mM dNTP, 2 mM Mg(OAc) 3 , 1 1 XL buffer, and 2 U of XL DNA polymerase (Perkin-Elmer Applied Bio-PCR product sequencing with 5CAI 2238 and 3CAI 2626. All sequences were determined from both strands and aligned with systems, Foster City, CA). Denaturation at 94ЊC for 2 minutes was followed by 35 cycles at 94ЊC for 15 seconds, 54ЊC for the wild-type reference sequence for HIV-1 [24] by using Sequencher (Gene Codes, Cambridge, MA). 30 seconds, and 68ЊC for 2 minutes with an autoextension of 5 seconds in the last 15 cycles and a final extension at 68ЊC
HIV-1 culture. Culture of seminal and blood plasma and leukocytes was performed on PBMC target cells activated with for 10 minutes. Six microliters of this reaction mixture was used in the second round with the same reaction mixture except phytohemagglutinin/IL-2 as previously described [16] .
Detection of HIV in blood.
Because of site-specific technical for 0.8 mM Mg(OAc) 3 and the inner primers 5CAI2027 (HxB2 positive-strand nucleotides 2,026 to 2,056) and 3CAI4150 difficulties, plasma and PBMC specimens before indinavir therapy were not available for subsequent PCR analyses for HIV-1 RNA (HxB2 negative-strand nucleotides 4,149 to 4,122). Denaturation at 94ЊC for 1 minute was followed by 30 cycles at 94ЊC
and DNA at the time that paired semen specimens were tested. However, plasma HIV-1 RNA assays (branched DNA assay; for 15 seconds, 62ЊC for 30 seconds, and 68ЊC for 1.5 minutes with a final extension at 72ЊC for 10 minutes. The third round Chiron Corporation, Emeryville, CA) were performed for all participants at the time that semen specimens were obtained, as part was performed with 6 mL of the previous amplification product with use of primers 5CAI2238 (HxB2 positive-strand nucleoof ongoing clinical care [25] . At the time that the study began (1996), the first-generation assay (limit of detection, 10,000 RNA tides 2,237 to 2,268) and 3CAI2626 (HxB2 negative-strand nucleotides 2,626 to 2,597), 1.1 mM Mg(OAc) 3 and the followcopies/mL) was the only means available for the clinic to quantify plasma levels of HIV-1 RNA, and specimens were not saved. By ing thermal cycling parameters: 94ЊC for 1 minute, 94ЊC for 10 seconds, 25 cycles of 65ЊC for 45 seconds, and a final the time that the absence of intact baseline blood specimens was noted, the clinic switched to the more sensitive second-generation incubation at 72ЊC for 10 minutes.
The final PCR product was 388 bp long and included all branched DNA RNA-1 assay (Chiron), which has a limit of detection of 500 RNA-1 copies/mL. protease coding sequences. Control peripheral blood mononuclear cell lysates from seronegative donors were used in each Statistical methods. The prevalence of detectable seminal HIV-1 RNA or DNA before and 6 months after the addition step of PCR analysis and remained negative. The baseline se-/ 9c68$$ju02 05-11-99 12:19:26 cida UC: CID * Determinations of baseline plasma levels of HIV were done by using the first-generation branched DNA assay (Chiron Corporation, Emeryville, CA); subsequent analysis utilized the second-generation assay, which has a limit of detection of 500 copies/mL. † As cell-free or cell-associated RNA or cell-associated DNA. ‡ Two participants elected not to participate in the study at 6 months.
of indinavir therapy was compared by the Student's t test [26] . of eight) than in those from men with plasma viral loads of õ10,000 copies/mL (six of 14), but this difference was not Other statistical comparisons included assessment of the magnitude of HIV-1 RNA or DNA in plasma or peripheral blood statistically significant (table 1) . mononuclear cells in relation to the detection of HIV-1 in Before the addition of indinavir to combination chemotherseminal plasma or leukocytes.
apy, HIV was detected as proviral DNA in semen specimens from 21% of the men, as cell-associated RNA in semen specimens from 32% of the men, and as cell-free RNA in semen Results specimens from 32% of the men (table 2) . Prior to the addition of indinavir, the highest viral concentrations ranged from The study population included 22 asymptomatic HIV-posi-70,000 copies of cell-associated RNA/mL to 400,000 copies tive men who never had an AIDS-related opportunistic infecof cell-free RNA/mL. However, by 1 month after the initiation tion, even though six (27%) of the men had CD4 cell counts of indinavir therapy, the detection of cell-associated and cellof õ200/mL. At the onset of the study, two of the men had free RNA markedly dropped and was found only in about 9% prior diagnoses of Kaposi's sarcoma, and three others had one and 5% of the participants' samples, respectively. Semen cell of the following HIV-associated conditions: oral hairy leuko-DNA was more readily detected throughout the study, although plakia, recurrent oral herpes simplex, and thrush. At the time the maximum concentration following treatment (800 of enrollment, all participants were asymptomatic and had been copies/mL) was 2 logs less than the maximum concentration receiving dual nucleoside analog antiretroviral therapy for at before the commencement of therapy. least 6 months. Before the addition of indinavir to the therapeuAfter 6 months of therapy, HIV DNA was amplified from tic regimen, 14 (64%) of 22 participants had HIV-1 RNA levels the semen cells from four of 18 men for whom paired samples of õ10,000 copies/mL, and by 6 months, 14 (70%) of 20 had were available (i.e., 22%, identical to the prevalence of baseline plasma levels of HIV-1 RNA of õ500 copies/mL. HIV-1 RNA semen samples that had detectable HIV DNA). The maximum was detected in the seminal plasma of seven (32%) of 22 men concentration was 3,000 copies/mL (table 2) . There was only at baseline and in the seminal plasma of only one (5%) of 19 one individual for whom both cell-associated RNA and cellafter 6 months. However, HIV RNA or DNA was detected by free RNA were detected after 6 months of combination therapy PCR analysis of semen specimens from 13 (59%) of 22 men (27,000 and 10,000 copies/mL, respectively). Cultures of blood at baseline, before indinavir was added to their treatment regiand semen specimens from the four men who had seminal HIV mens, and it remained detectable in semen specimens obtained DNA detected after 6 months of therapy were performed. None 6 months later from four (31%) of 13 men who had positive of the semen cultures and only one of the blood cultures were baseline semen specimens (table 1) .
positive for HIV. The median CD4 cell count for the 14 men with plasma The one individual (patient A) who continued to have both viral loads of õ10,000 copies of HIV RNA/mL at the outset HIV RNA and HIV DNA detected in his semen had a peripheral of the study was 246/mL (range, 81 -599/mL), which was not blood CD4 cell count of 144/mL and a viral load of õ10,000 statistically different from that for the eight men who had copies/mL (determined by the first-generation branched DNA baseline viral loads of ú10,000 copies/mL (median CD4 cell assay) when he began the study. His prior antiretroviral treatment count, 234 cells/mL [range, 99 -632/mL]) (table 1). HIV was included zidovudine and lamivudine. However, during the course detected more frequently by PCR analysis in semen specimens from men with peripheral blood viral loads of ú10,000 (seven of this study, the patient complained of increasing nausea after / 9c68$$ju02 05-11-99 12:19:26 cida UC: CID starting indinavir therapy and began to skip occasional doses. By Although the 6-month semen cell DNA specimen from patient B had a lower viral load than did that from patient A and 5 months into the study, he discontinued therapy with zidovudine and indinavir, and his treatment was switched to stavudine and HIV RNA was not detected in semen, the protease amino acid sequence from the 6-month specimen from patient B was somesaquinavir with continuation of lamivudine administration. The patient believed that this regimen was more tolerable and indiwhat genetically diverse and differed from the baseline sequence in several positions, including some conferring resiscated he was able to be compliant, unlike with indinavir. His CD4 cell count at the 6-month visit was 122/mL, with a peripheral tance to protease inhibitors [24, 25] (table 3) . V77I dominated in the semen viral population (10 of 10 clones) at 6 months blood viral load of 900 copies/mL.
HIV DNA was detected in the semen cells of three other but not at baseline, and M46L was present in one of the 10 clones at 6 months [27]. Substitutions were also seen in minorparticipants at 6 months who did not report difficulty in complying with their medication regimens. Despite reported comity subpopulations in this semen specimen in protease codons 36 (three of 10 clones) and 54 (one of 10 clones). These results pliance, one participant (patient B) for whom proviral DNA was detected in semen at 6 months had a plasma viral load of indicate that a few genomes with at least two protease codon substitutions that may contribute to indinavir resistance were 9,100 copies/mL at 6 months and a CD4 cell count of 516/mm 3 . The other two men who had proviral DNA detected present in the HIV-1 population in the 6-month semen sample from patient B that was obtained when the plasma RNA level in their semen had peripheral blood viral loads of õ500 copies/mL (determined by the second-generation branched was 9,100 copies/mL. DNA assay), and they had CD4 cell counts of 327 and 617/mm 3 at 6 months compared with baseline CD4 cell counts Discussion of 556 and 251/mm 3 , respectively. HIV-1 protease genes were amplified, cloned, and sequenced Combination therapy with protease inhibitors has been a major advance in treatment of HIV-1 infection [1 -3, 14, 15, from the baseline and 6-month semen cell DNA specimens from patients A and B but were not amplified with the sequenc-28]. The plasma viral load is suppressed in most patients treated with these regimens by ú2 logs to levels that are below the ing primers from any specimens from either of the other two patients with persistent semen cell HIV DNA. Semen and blood limit of detection for §1 year [2, 14, 15, 28] . Indeed, if such therapy suppressed the viral load in semen as well as in plasma cell specimens were also obtained from patient A after 18 months of therapy, and HIV DNA was amplified from these and drug-resistant mutants were not detectable in semen, it would be reasonable to hypothesize that the epidemic spread specimens. The protease genes amplified from the semen cell DNA specimen from patient A at baseline were genetically of HIV-1 could be significantly altered by potent combination regimens including a protease inhibitor. Because of the impresdistinguishable from those amplified in the subsequent 6 months, suggesting viral evolution had occurred between those sive reductions in plasma levels of HIV-1 RNA during protease inhibitor -containing triple combination therapy, the current two times. Despite this occurrence and the detection of seminal plasma and semen cell HIV RNA, protease resistance mutations study was designed to evaluate the long-term effects of a protease inhibitor -containing regimen on the HIV-1 load and resiswere not identified, and a relatively genetically homogeneous viral population was observed in the semen cell DNA specimen tance in semen.
Of the men in this study, 59% had seminal HIV detectable from patient A at 6 months when his plasma viral load was 900 copies/mL (table 3). Eighteen months after patient A started to as either amplifiable HIV RNA or DNA before starting combination therapy including indinavir. After 6 months of treatment, receive the protease inhibitor -containing regimen, resistance had evolved in both seminal and blood leukocyte HIV DNA, significantly fewer (20%) had detectable HIV RNA or DNA in semen (P Å .026). However, amplified HIV persisted in with genetic differences detected in the viral DNA from each compartment.
semen from four (31%) of 13 men with detectable HIV at the / 9c68$$ju02 05-11-99 12:19:26 cida UC: CID NOTE. All relevant differences (from the HxB2 reference sequence and/or other patient sequence) are indicated. One clone each from the semen cell DNA specimens from patient A at baseline and at 18 months and one clone from the blood cell DNA specimen from patient A at 18 months had a stop codon and frameshift early in the protease reading frame, precluding amino acid sequence determination. ND Å not determined; WT Å wild type; . . . Å identity with HIV-1 HxB2 reference sequence.
start of indinavir therapy. None of the men who had seminal centration in plasma is greater than that in genital tract secretions, even in very early HIV infection [31] . HIV DNA detected at 6 months had clinical evidence of active genital tract infections, and three of four of these men reported Since combinations of two nucleoside analog reverse transcriptase inhibitors initially decreased the systemic HIV burden full compliance with their treatment regimens, raising concerns that systemic suppression of HIV replication may not invariably by õ2 logs [15 -18] and seminal HIV concentrations may often be ú1,000 copies/mL, it is not surprising that such earlier correlate with control of viral expression in the genital tract even in the absence of such factors.
regimens did not invariably lead to undetectable levels of seminal HIV. Moreover, several studies have demonstrated that Although HIV detection by PCR analysis of semen tended to parallel plasma levels of HIV RNA, two men with undetectable reverse transcriptase inhibitor -resistant HIV may be sexually transmissible [19 -22] , indirectly indicating that reverse tranplasma levels of HIV RNA had seminal HIV DNA detected after 6 months of indinavir-containing triple combination therscriptase mutants are present in semen during such therapy. Another recent study [34] documented the independent emerapy. It is possible that indinavir and/or other antiretroviral drugs could have relatively poor penetration into male genital tract gence of HIV-1 resistance in the peripheral blood and seminal compartments of men before and after changes in their antiretsecretions and/or decreased drug availability in semen because of binding to any of a number of prevalent seminal proteins. roviral therapy, demonstrating the partial separation of viral replication in the blood and the genital tract. The lack of identiThese men could have had occult genital tract infections resulting in localized upregulation of HIV expression. One man cal replication could be due to differential cytotropism in the different tissues, variable penetration of antiretroviral therapy with a peripheral blood viral load of 19,600 copies/mL had no seminal HIV detected (table 1) . Discordance between HIV levin different compartments, or other factors that will require further study. els detected in blood and semen specimens has been reported previously, and both advanced immunosuppression [9, 18, 29] Despite the greater reductions in viral load during protease inhibitor-containing combination regimens, this study showed and local factors such as genital tract infection [30 -32] have been implicated. Asymptomatic HIV-positive individuals with that protease inhibitor-resistant HIV-1, as well as protease inhibitor-susceptible HIV-1, can be present in the semen of pamarkedly elevated seminal leukocyte counts have been described, and these persons could be particularly infectious to tients receiving protease inhibitor-containing regimens. The dominant V77I substitution that emerged in semen cell DNA their sexual partners [11, 33] here reflect suboptimal effects of adding one new drug to the regimen. Simultaneous initiation of several new drugs may effect was associated with phenotypic indinavir resistance in a regression analysis with borderline (P Å .065) statistical signifihave resulted in more complete suppression of viral replication in semen. However, given the fact that significant numbers of cance [27] . The substitution has also been documented to be absent before indinavir therapy is started and to emerge in asymptomatic HIV-positive men have been shown to have genital tract leukocytosis [11, 33] , often with ú1 million plasma HIV-1 RNA during indinavir-containing combination therapy for several other patients (R. D'Aquila, unpublished WBCs/mL of semen, the importance of detection of proviral DNA in semen cannot be minimized. We have previously data). V77I is also associated with nelfinavir resistance [35] , which patient B never received. Although a single protease inshown that cell-associated RNA is a significant part of the HIV load in the genital tracts in untreated individuals [11] ; HIVhibitor resistance mutation is unlikely to cause appreciable phenotypic resistance to indinavir, minority subpopulations with infected leukocytes have been sufficient to cause infection in primates without cell-free RNA in seminal plasma [38] . additional mutations were also detected, including one confirmed additional protease inhibitor resistance mutation (M46L) and
Since HIV remains detectable in semen specimens from some patients compliant with treatment, health care providers two as yet uncharacterized substitutions in positions where other amino acid substitutions do confer protease inhibitor resistance and educators need to continue to remind HIV-positive persons and their partners that neither triple combination therapy nor (amino acids 36 and 54) [27] . Studies also support the importance of minority subpopulations of HIV in semen for sexual an undetectable systemic HIV load alleviates the need to continue to avoid mucosal exposure to HIV-infected semen. Recent transmission; it is generally a minor variant rather than the dominant virus in semen populations that is found in the recipient's reports of new sexually transmitted diseases and HIV infections in young homosexual men [39] and heterosexually active popublood following sexual transmission [32] .
The data in the current study indicate that semen is a potential lations [40] underscore the importance of not equating effective clinical responses to highly active antiretroviral therapy with reservoir for protease inhibitor -resistant HIV-1. In vitro studies have shown that some protease inhibitor -resistant mutants the elimination of infectiousness. with multiple substitutions replicate in the absence of drug as well as wild-type virus even though other protease inhibitorresistant mutants with fewer mutations have impaired replica-
